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ABSTRACT 
The hypothalamus is critical to the coordination of energy balance and glucose homeostasis. It 
responds to peripheral factors such as insulin and leptin that convey to the brain the degree of 
adiposity and the metabolic status of the organism. The development of leptin and insulin 
resistance in hypothalamic neurons appears to play a key role in the exacerbation of diet-
induced obesity. In rodents, this has been attributed partly to the increased expression of the 
tyrosine phosphatases PTP1B and TCPTP that attenuate leptin and insulin signaling.  
Deficiencies in PTP1B and TCPTP in the brain, or specific neurons, promote insulin and leptin 
signaling and prevent diet-induced obesity, type 2 diabetes and fatty liver disease. Although 
targeting phosphatases and hypothalamic circuits remain challenging, recent advances indicate 
that such hurdles might be overcome. Here we focus on the roles of PTP1B and TCPTP in 
insulin and leptin signalling and explore their potential as therapeutic targets. 
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OBESITY EPIDEMIC 
Although obesity has been evident for millennia, its prevalence only began to rise in the 
last century. Between 1980 and 2013 the prevalence of overweight (BMI > 25 kg/m2) and obese 
(BMI > 30 kg/m2) individuals rose by 27.5% in adults and 47.1% in children, so that by 2013 
there were 2.1 billion overweight and 671 million obese people worldwide. Excess body weight 
is a major and leading factor in overall disease burden and if left unabated could lead to 
decreases in life expectancy, particularly in developed nations [1]. Notably, the obesity 
epidemic is the single most important contributor to the development of type 2 diabetes (T2D), 
a major cause of obesity-associated morbidity and mortality [2, 3]. 
The environmental, genetic and socioeconomic factors underlying the development of 
obesity are complex. Its increasing prevalence highlights that dietary and lifestyle interventions 
alone are unlikely to be effective in combating the rising tide of obesity, and underscores the 
need for novel therapeutic approaches. To achieve this it is important that we understand the 
molecular perturbations that promote obesity and its complications. Large genome-wide 
association studies and meta-analyses suggest that >20% of BMI variation may be accounted 
for by common genetic variation and have highlighted the principal importance of central 
nervous system (CNS) pathways in obesity [4]. CNS leptin and insulin pathways are important 
in the control of appetite, energy expenditure and glucose homeostasis [5] and molecules that 
antagonise leptin and insulin signaling in obesity may provide effective targets for therapeutic 
intervention. Prominent among such targets are the protein tyrosine phosphatases (PTPs) that 
dephosphorylate tyrosine-phosphorylated substrates to antagonise insulin and leptin-induced 
signaling [6, 7]. This review will focus on the role of classical PTPs, in particular PTP1B and 
TCPTP, in the CNS control of body weight and glucose homeostasis and explore approaches 
for inhibiting neuronal PTPs to combat obesity and T2D. 
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PTPs & OBESITY 
Leptin Signaling 
Leptin is a 16 kDa cytokine that is produced by white adipocytes in approximate proportion 
to white adipose tissue (WAT) mass [8-10]. Leptin coordinates energy balance primarily via 
hypothalamic circuits that control feeding, movement, thermogenesis and glucose homeostasis 
[11-15]. Leptin’s effects are additionally mediated by other regions of the brain, including for 
example the brainstem [16-18]. Leptin is transported across the blood brain barrier (BBB) by a 
saturable system [19]; transport into the cerebrospinal fluid (CSF) may be reliant on leptin 
signaling in median eminence tanycytes, specialised glial cells that extend from the third 
ventricle to the permeable fenestrated capillaries of the BBB [20] (Figure 2). 
The arcuate nucleus (ARC), located in the basal part of the hypothalamus, is considered to 
have a fundamental role in sensing the global energy status of the organism, containing neurons 
that respond to peripheral stimuli such as leptin, insulin, ghrelin, glucose and free fatty acids 
[21-23].  The ARC contains two opposing neuronal populations: the appetite-suppressing 
proopiomelanocortin (POMC) [precursor of α-melanocyte-stimulating hormone (α-MSH)] and 
the orexigenic neuropeptide Y (NPY) and AgRP-neuropeptide expressing neurons (Figure 2). 
POMC neuronal activation promotes α-MSH release to agonise melanocortin-4 receptors 
(MC4Rs) on ‘second order’ neurons in regions such as the paraventricular nucleus (PVN) of 
the hypothalamus, to control food intake, energy expenditure and metabolism [5].  Leptin 
depolarises (activates) POMC neurons to promote α-MSH release, but hyperpolarises (inhibits) 
AgRP/NPY neurons and inhibits the release of AgRP and GABA that otherwise inhibit POMC 
neurons and antagonise α-MSH/MC4R interactions in the PVN [5, 24-26] (Figure 2). The 
principal role of the melanocortin system in body weight control is underscored by the marked 
obesity evident in humans and rodents with null mutations in the genes encoding leptin, LEPR-
B, POMC or MCR4 [27]. 
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Leptin signals via LEPR-B, a cell surface receptor that is associated with the protein 
tyrosine kinase (PTK) Janus-activated kinase 2 (JAK2) [28].  Leptin binding to LEPR-B 
activates JAK2, which in turn phosphorylates LEPR-B on tyrosines 985, 1077 and 1138. LEPR-
B Y1138 phosphorylation recruits STAT-3 via its SH2 domain [28].  STAT-3 is phosphorylated 
by JAK2 on Y705 to allow for STAT3 dimerisation and translocation to the nucleus to increase 
Pomc expression and inhibit Agrp expression [28, 29]. Leptin/LEPR-B also signals via JAK2 
and the PI3K/AKT pathway to regulate neuronal excitability and AMPK activation and FoxO1 
phosphorylation to alter neuropeptide expression and glucose metabolism [28-30]. These and 
other leptin signaling pathways elicit leptin’s effects on energy balance and glucose 
homeostasis (Figure 3). 
 
Insulin Signaling 
Insulin is released from pancreatic β cells following a rise in blood glucose and acts via 
the insulin receptor (IR) PTK and the PI3K/AKT pathway in liver, muscle and WAT to lower 
blood glucose levels and prevent post-prandial hyperglycemia. Insulin also acts in different 
regions of the brain to regulate, not only glucose homeostasis, but also energy balance, growth, 
reproduction, cognition and neural plasticity [31-36]. For example ICV insulin administration 
can repress food intake [32, 34, 37], inhibit WAT lypolysis [36, 38] and promote WAT 
browning and energy expenditure [39]. 
Insulin’s CNS effects on whole-body glucose metabolism are mediated in part through 
the repression of hepatic glucose production [33, 40-42]. In the ARC, insulin binding results in 
IR activation and phosphorylation of insulin receptor substrate 2 (IRS-2) to recruit PI3K and 
activate the serine/threonine protein kinase AKT, which phosphorylates FoxO1 to increase 
POMC and decrease AgRP/NPY expression (Figures 2 and 3).  Besides altering neuropeptide 
expression, insulin-induced PI3K signaling stimulates ATP sensitive K+ channels (KATP) to 
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alter the electrical activity of POMC and AgRP neurons [43-45] (Figure 3). CNS insulin 
signaling lowers hepatic glucose production [33] and this can be blocked by the infusion of a 
KATP blocker into the mediobasal hypothalamus, or by hepatic vagotomy [42]. Moreover 
genetic ablation of IR [31] or IRS-2 [46] in the brain, or the ICV inhibition of PI3K [33, 35], 
results in defective glucose homeostasis in mice. Insulin is thought to elicit its effects via ARC 
neurons, since IR deletion in AgRP neurons results in impaired repression of hepatic glucose 
production [41]. In lean humans, intranasal insulin delivery, so that insulin enters the CSF, 
increases hypothalamic and autonomic activity and enhances whole-body insulin sensitivity 
[47, 48].  Thus the promotion of hypothalamic/ARC insulin sensitivity may provide a powerful 
means by which to independently combat the development of insulin resistance in obesity. 
 
PTPs and leptin signaling 
To date only a handful of protein tyrosine phosphatases (PTPs) have been implicated in 
leptin signaling, including SHP-2 that links LEPR-B to the Ras/MAPK pathway [49, 50], 
PTP1B [49, 51-54] and PTPε [55] that dephosphorylate JAK2, TCPTP [56] that 
dephosphorylates STAT3 [56], and phosphatase and tensin homologue (PTEN) [57] that 
attenuates PI3K signaling (Figure 3). Here we will focus on the roles of PTP1B and TCPTP 
since their elevated hypothalamic expression has been implicated in leptin resistance and diet-
induced obesity [51, 56, 58]. 
PTP1B dephosphorylates the Y1007/Y1008 site in the JAK2 PTK activation loop [59] 
(Figure 3). JAK2 Y1007/Y1008 phosphorylation is enhanced in Ptpn1–/– fibroblasts [52], and 
the PTP1B-D181A substrate-trapping mutant [60] can form a complex with Y1007/Y1008-
phosphorylated JAK2, but not tyrosine-phosphorylated LEPR-B or STAT3 in LEPR-B-
overexpressing cells [53].  PTP1B’s role in the control of energy homeostasis and hypothalamic 
leptin sensitivity was brought to light by the generation of Ptpn1–/– mice, which were resistant 
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to diet-induced obesity [61, 62], and later by the deletion of PTP1B in neuronal and glial cells 
using the Nestin-Cre transgene [51]. Nestin-Cre;Ptpn1fl/fl mice were resistant to diet-induced 
obesity, had reduced food intake and exhibited increased energy expenditure, ambulatory 
activity and leptin sensitivity [51].  The bulk of this phenotype was later recapitulated in mice 
lacking PTP1B in LEPR-B-expressing cells [54]. By contrast, mice lacking PTP1B in POMC 
neurons had a mild phenotype [39, 49]. Therefore, the overt effects of PTP1B deficiency on 
food intake and energy expenditure might be ascribed to other neurons, or other regions of the 
brain where PTP1B deficiency also promotes leptin sensitivity [54]. 
  TCPTP also negatively regulates the leptin response [56] and is expressed in POMC 
[39] and AgRP neurons. TCPTP attenuates leptin signaling through the dephosphorylation of 
nuclear STAT3 [56] (Figure 3). TCPTP deletion in the brain (Nestin-Cre;Ptpn2fl/fl) promotes 
leptin-induced STAT3 signaling in the ARC and alters Pomc and Agrp expression and α-MSH 
secretion [56]. Furthermore, Nestin-Cre;Ptpn2fl/fl mice exhibited an overall improvement in 
leptin sensitivity associated with decreased food intake, reduced adiposity and increased energy 
expenditure [56] that could be recapitulated by the ICV administration of a specific TCPTP 
inhibitor in C57BL/6 mice [56]. By contrast to PTP1B, TCPTP is redundant in leptin signaling 
in POMC neurons [39]; TCPTP deletion in POMC neurons (Pomc-Cre;Ptpn2fl/fl) did not 
promote leptin-induced STAT3 phosphorylation or the effects on food intake or body weight 
[39]. Defining TCPTP’s role in leptin signaling will require further investigation and an 
assessment of TCPTP function in other hypothalamic neurons and cell types. 
 
PTPs and insulin signaling 
 Several PTPs have been shown to attenuate insulin signaling in peripheral tissues, but 
PTP1B is arguably the most critical [6]. PTP1B dephosphorylates the IR Y1162/Y1163 site and 
potentially IRS-1/2 to attenuate insulin signaling [6]. Ptpn1–/– mice, or liver- or muscle-
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specific PTP1B-deficient mice exhibit enhanced IR phosphorylation and signaling in liver and 
muscle and improved glucose homeostasis [51, 61-63].  
There is evidence that PTP1B might also attenuate insulin signaling in the hypothalamus. 
PTP1B knockdown using antisense oligonucleotides enhances insulin signaling and promotes 
insulin-induced satiety to repress weight gain [64], whereas binge drinking has been shown to 
promote hypothalamic PTP1B expression to suppress the insulin-mediated repression of HGP 
[65]. However, PTP1B’s role may be cell type-dependent, since PTP1B deletion in SF-1 
neurons in the ventromedial hypothalamus enhances insulin signaling to suppress energy 
expenditure and promote weight gain in female mice [66], whereas PTP1B deletion in POMC 
neurons in the ARC has no effect on insulin signaling and glucose homeostasis, but enhances 
leptin signaling [39].  Rather, in POMC neurons, TCPTP may be the principal phosphatase 
attenuating insulin signaling [39]. TCPTP can dephosphorylate the IR Y1162/Y1163 site to 
attenuate insulin signaling [67] and TCPTP-deficiency in POMC neurons results in enhanced 
insulin-induced AKT Ser-473 phosphorylation and Pomc expression and improved glucose 
homeostasis [39]. Therefore, PTP1B and TCPTP may differentially contribute to ARC leptin 
and insulin signaling to regulate the melanocortin response (Figure 3). 
 
Leptin and Insulin Resistance 
Obesity and T2D are characterised by the development of insulin resistance and ‘cellular’ 
leptin resistance [68-70].  Insulin resistance involves the diminished responsiveness of insulin’s 
key target tissues to insulin and has been attributed to varied factors including inflammation, 
ER stress and oxidative stress, which accompany the obese state [69-71].  Insulin resistance in 
liver, muscle and WAT is early hallmark of T2D and a driving factor in disease progression 
[69, 70]. Hypothalamic insulin resistance also occurs in obesity [72-74], but the extent to which 
this contributes to the pathogenesis of T2D remains unclear. 
 9 
Whether ‘cellular’ leptin resistance initiates weight gain in obese humans remains 
incompletely understood. However, it is widely accepted that the increased adiposity associated 
with overfeeding promotes cellular leptin resistance in ARC neurons to exacerbate diet-induced 
obesity [68]. A number of mechanisms are thought to contribute to the development of cellular 
leptin resistance (and CNS insulin resistance). These include reduced transport across the BBB 
[75-77] and the enhancement of intracellular processes that attenuate LEPR-B signaling, 
including inflammation and ER stress [72, 78, 79] that drive the expression of negative 
regulatory molecules, such as suppressor of cytokine signaling 3 (SOCS3) and PTP1B [51-53, 
58, 80, 81]. In rodents, genetic and pharmacological approaches that interfere with such 
negative regulatory processes promote LEPR-B signaling and thereby resistance to diet-
induced obesity [51-53, 64, 79-83]. For example, overexpression of the unfolded protein 
response transcription factor Xbp1s in POMC neurons decreases PTP1B and SOCS3 
expression, improves leptin and insulin sensitivity and liver metabolism and protects against 
diet-induced obesity [84]. Not surprisingly, deficiencies in neuronal PTP1B and SOCS3 
promote leptin sensitivity and attenuate diet-induced obesity [51, 80-82].   
The hyperleptinemia associated with the increased adiposity in obesity also promotes 
the feedback inhibition of leptin signalling by TCPTP [56]. Acute leptin administration 
increases hypothalamic TCPTP mRNA and protein expression and hypothalamic TCPTP levels 
are increased in obese C57BL/6 mice, but not leptin-deficient Ob/Ob mice [56]. The increased 
expression of PTP1B and TCPTP in the hypothalamus is thought to result in the consolidated 
repression of the leptin (at the level of JAK2 and STAT3) and insulin signals, thereby 
exacerbating obesity and the development of T2D.  Testament to this is that the combined 
deletion of PTP1B and TCPTP in neuronal and glial cells [56] or POMC neurons [39] results 
in the striking attenuation of diet-induced obesity (greater than that achieved by the deletion of 
either PTP alone), and markedly improved leptin sensitivity and glucose homeostasis. A direct 
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assessment of PTP1B and TCPTP protein levels in the hypothalami of obese versus lean 
humans remains a challenge. However, it is known that in obese rodents, hypothalamic and 
skeletal muscle PTP1B protein levels are elevated as a consequence of inflammatory signalling 
[58]. Since obesity is associated with inflammation and PTP1B is elevated in human skeletal 
muscle in obesity [85], it is highly likely that hypothalamic PTP1B is also increased in obese 
humans. Furthermore, since leptin drives the expression of TCPTP in vitro and in vivo [56], it 
seems probably that hypothalamic TCPTP will also be elevated in obese hyperleptinemic 
individuals. Therefore, inhibiting both PTP1B and TCPTP in the ARC might be effective in 
ameliorating cellular leptin resistance and insulin resistance to combat diet-induced obesity. 
 
PTPs and the CNS control of WAT browning 
 Recent studies have elucidated the principal role of the ARC in surveying peripheral 
energy reserves as conveyed by the combined actions of insulin and leptin and promoting 
energy expenditure through the sympathetic innervation of WAT (stores energy) and the 
increased formation of so-called ‘beige’ fat (expends energy) [39], a process referred to as WAT 
browning [86] (Figure 4). Promoting WAT browning in rodents prevents diet-induced obesity 
and T2D [87, 88], whereas in humans, brown/beige fat depots are diminished in obesity [89].  
In rodents, POMC neuronal activation increases WAT browning [39], whereas fasting and 
AgRP neuronal activation represses browning and energy expenditure [90], in keeping with the 
process being responsive to changes in energy status. PTP1B and TCPTP are expressed in both 
overlapping and anatomically distinct POMC neurons in the ARC and differentially contribute 
to the control of leptin and insulin signaling [39]. Their combined deficiency in POMC neurons 
and the promotion of both leptin and insulin signaling resulted in robust WAT browning, 
increased energy expenditure and afforded a remarkable resistance to diet-induced obesity and 
glucose intolerance and the development of hepatosteatosis [39]. Combined deficiencies in 
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PTP1B and TCPTP in POMC neurons also increased interscapular brown adipose tissue (BAT) 
thermogenesis, but this was not due to the leptin/insulin synergy, but rather the promotion of 
leptin sensitivity [39]. Although POMC neurons in the nucleus of the solitary tracts of the 
hindbrain might also impact on BAT thermogenesis, TCPTP is not expressed in POMC neurons 
in this region of the brain [39], consistent with the synergistic effects on BAT thermogenesis 
being ascribed to the ARC. Irrespective, dampened responses of ARC POMC neurons and 
potentially AgRP neurons to circulating insulin and leptin, as a consequence of elevated levels 
of the inhibitory phosphatases PTP1B and TCPTP, might suppress WAT browning and energy 
expenditure and thereby exacerbate the development of obesity (Figure 4). Hence, the 
combinatorial inhibition of PTP1B and TCPTP in the hypothalamus/ARC may afford a means 
for not only promoting leptin-induced JAK2 and STAT3 signaling, but also the integrated 
response to leptin and insulin to increase WAT browning and energy expenditure to combat 
diet-induced obesity. 
 
PTP INHIBITORS 
PTP-based drug discovery has historically been shrouded with difficulties in attaining 
inhibitor selectivity and bioavailability, but in recent years these challenges have been 
convincingly met, through various approaches, including the generation of drugs targeting both 
the highly conserved phosphotyrosine (pTyr)-binding pocket [91] and adjacent substrate-
binding pockets, and through the generation of allosteric inhibitors [92], which can bind distant 
sites including disordered regions in PTP non-catalytic domains [93]. 
To address the issue of inhibitor potency and selectivity when targeting the pTyr-
binding pocket [91], one can take advantage of amino acids and substrate-binding pockets that 
flank the active site and contribute to PTP substrate selectivity [94]. Accordingly, a novel 
paradigm was advanced for the design of potent and selective bivalent PTP inhibitors [95] by 
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tethering appropriate diversity elements to a nonhydrolyzable pTyr mimetic to engage both the 
active site and nearby unique peripheral binding pockets. Bivalent PTP inhibitors are expected 
to possess enhanced affinity and selectivity due to additivity of free energy of binding and lack 
of structural similarity for second site interaction among different PTPs. To overcome the issue 
of bioavailability, several novel nonhydrolyzable pTyr mimetics have been discovered over the 
last few years that are sufficiently polar to bind the PTP active site, yet remain capable of 
efficiently crossing cell membranes [96, 97]. These pTyr mimetics interact in the desired 
inhibitory fashion with the PTP active site and the molecular scaffolds attached to them render 
the inhibitors PTP isozyme-selective. Recent studies using fragment-based and structure-
guided approaches to target both the PTP active site and adjacent less conserved pockets 
demonstrate that it is feasible to obtain PTP inhibitors with high affinity, selectivity, and 
excellent in vivo efficacy in animal models of oncology, diabetes/obesity, autoimmunity, and 
tuberculosis [98]. In addition to the active site-directed approach, another promising method that has been gaining significant traction in PTP drug discovery is targeting 
allosteric sites in PTPs that are less conserved, which has been demonstrated to be a good 
strategy for the development of inhibitors with high specificity and cell permeability [92]. 
In the following we highlight several inhibitors of PTP1B and TCPTP that have been 
used to further validate both phosphatases as therapeutic targets (Figure 5). Compound 1 was 
identified from a focused library approach with a Ki value of 2.4 nM for PTP1B and several 
orders of magnitude selectivity in favor of PTP1B against a large panel of PTPs [99]. More 
importantly, compound 1 also displays >10-fold selectivity in favor of PTP1B over TCPTP, 
which is closely related to PTP1B (72% catalytic domain sequence identify) [6]. Biochemical 
and structural studies show that compound 1 simultaneously occupies both the active site and 
a unique peripheral site in PTP1B [100]. As expected, compound 2, a cell permeable derivative 
of 1, is capable of augmenting insulin signaling and improving insulin sensitivity [101]. To 
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more directly examine the role of PTP1B in leptin resistance, the effect of local inhibition of 
hypothalamic PTP1B was tested in 20-week old, leptin-resistant rats [102]. Acute ICV 
administration of compound 2 markedly improved the anorectic effects of leptin in 20-week 
old, leptin-resistant rats, indicating that hypothalamic PTP1B inhibition may be beneficial in 
alleviating leptin resistance. Compound 3 contains an isothiazolidinone (IZD) group as a pTyr 
mimetic and exhibits an IC50 of 10 nM for PTP1B and increased IR phosphorylation level in a 
dose-dependent manner [103]. Although compound 3 does not discriminate between PTP1B 
and TCPTP, it provides a proof of concept that heterocycles such as IZD can serve as highly 
efficacious pTyr mimetics. A dibenzo[b,d]furan mono-carboxylic acid derivative 4 was found 
to inhibit PTP1B with an IC50 value of 82 nM and over 20-fold selectivity against TC-PTP 
[104]. Compound 4 was tested in vivo for anti-diabetic activity and showed significant efficacy 
in reducing body weight, fed- and fasting-state whole blood glucose, and plasma cholesterol 
levels in Ob/Ob mice. Compound 5 represents another PTP1B inhibitor with a Ki of 0.2 µM 
and greater than 46-fold selectivity over TCPTP and the receptor phosphatases CD45, and LAR 
[105]. Compound 5 is capable of increasing insulin-stimulated glucose uptake in L6 cells and 
insulin signaling in ob/ob mice. Chronic administration compound 5 exerted a hypoglycemic 
effect without body weight gain.  
In addition to the active site-directed PTP1B inhibitors described above, there is also 
substantial interest in an allosteric PTP1B inhibitor trodusquemine (also known as MSI-1436; 
compound 6), which was discovered serendipitously. Trodusquemine was originally discovered 
among a family of aminosterol compounds in the tissues of dogfish shark with broad-spectrum 
antimicrobial activity as well as potent appetite suppressant and antidiabetic properties [106-
108]. Subsequent investigation revealed that trodusquemine functioned as a potent 
noncompetitive inhibitor of PTP1B with a 200-fold preference (IC50 of 1 μM vs. 224 μM) over 
TCPTP [83]. The ability of trodusquemine to cause rapid and reversible weight loss in both 
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genetic and diet-induced models of obesity has been further verified in additional studies [83, 
109]. Through a series of elegant experiments, it was demonstrated that trodusquemine inhibits 
preferentially the full-length form of PTP1B, containing the regulatory C-terminal disordered 
fragment, thus revealing a novel mechanism of PTP1B allosteric inhibition [93]. It is anticipated 
that trodusquemine and/or its derivatives have the potential for treating T2D/obesity and other 
conditions with upregulated PTP1B activity, including breast cancer where PTP1B contributes 
to ErbB2/HER2-mediated tumorigenicity [93, 110]. 
Compared to PTP1B, much less drug discovery effort has been focused on TCPTP. 
Nevertheless, a fragment-based library synthesis and screening strategy led to the discovery of 
compound 7, an extremely potent and selective TCPTP inhibitor [111]. Compound 7 is a 
competitive inhibitor of TCPTP with a Ki of 4.3 nM and is more than 200-fold selective versus 
a panel of mammalian PTPs. Furthermore, an eight-fold selectivity for TCPTP over its closest 
homologue PTP1B is observed. Importantly, ICV administration of compound 7 enhances 
leptin-induced STAT3 Y705 phosphorylation, represses food intake and body weight and 
increases energy expenditure in mice [56] and promotes induced Pomc expression [39]. 
Collectively, the available data suggest that PTP1B and TCPTP inhibitors are capable of 
enhancing insulin and leptin sensitivity whether applied systemically, or locally to the brain.  
 
Concluding remarks 
  Considerable progress has been made in defining the role of the phosphatases PTP1B 
and TCPTP in the CNS control of body weight. In particular recent studies have highlighted 
the potential for PTP1B and TCPTP to regulate the hypothalamic response to leptin and insulin 
and the promotion BAT thermogenesis, WAT browning and energy expenditure (). PTP1B and 
TCPTP levels are elevated in the hypothalamus in obesity, repressing leptin and insulin 
signaling and thereby perturbing energy balance ().  Their inhibition may afford opportunities 
for therapeutic intervention and assist in combating the obesity epidemic. Although the hurdle 
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of developing of selective PTP1B and TCPTP inhibitors has been demonstrably overcome, a 
significant albeit not insurmountable challenge remains in selectively targeting the brain. This 
is particularly important for TCPTP given its role in hematopoietic development and 
autoimmunity [112-115]. Although TCPTP heterozygous deficiency does not result in any 
overt immune phenotype [112], TCPTP heterozygoisty is sufficient to enhance T cell responses 
to self-antigen and autoimmunity, with age [115], in the context of lymphopenia [113] and in a 
mouse model of type 1 diabetes [114]. Despite this, recent work aimed at improving whole-
body insulin sensitivity through the intranasal application of insulin and the enhancement of 
hypothalamic and parasympathetic outputs in humans [47, 48, 74, 116], suggests that selective 
CNS delivery of PTP1B/TCPTP inhibitors might be a viable option.  Indeed the intranasal 
delivery of PTP1B/TCPTP inhibitors, directly into the CSF, may avoid the immune 
compartment and re-sensitise obese individuals to the beneficial CNS effects of insulin and 
leptin. Therefore dealing with the obesity and T2D epidemics with PTP inhibition might be just 
a puff away. 
 
BOX1: PTPs 
The PTP superfamily of enzymes comprises approximately 100 members that are defined by 
the active-site signature motif HCX5R [6, 117]. The catalytic domains of classical PTPs 
comprise approximately 280 residues with 22 invariant and 42 highly conserved residues 
organised into 10 consensus motifs. These motifs contribute to conserved elements in the 
tertiary structure and can be involved in substrate recognition or catalysis. The cysteine and 
arginine residues within the HCX5R signature motif are essential for catalysis. The cysteine 
(PTP1B Cys-215) is located at the base of a deep cleft on the PTP surface.  The depth of this 
cleft engenders specificity for phosphotyrosine- over phosphoserine/threonine-containing 
proteins, with the phosphatate moieties of the smaller phosphoserine and phosphothreonine 
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unable to reach the cysteine at the base. The sulfur atom of the thiolate group of the cysteine 
residue serves as a nucleophile and attacks the substrate phosphate. An aspartate (PTP1B Asp-
181) on another conserved motif, the WPD loop, serves as a general acid to protonate the 
phenolic oxygen of the tyrosyl leaving group of the substrate to form a cysteine-phosphate 
intermediate. The conserved arginine (PTP1B Arg-221) in the signature motif contributes to 
substrate binding and stabilizes the cysteine-phosphate intermediate.  In the second step of 
catalysis, the WPD loop aspartate acts as a general base and functions in concert with a highly 
conserved glutamine residue (PTP1B Gln-262) that coordinates a water molecule, to promote 
the hydrolysis of the cysteine-phosphate intermediate and release the phosphate. 
The human genome encodes 37 (38 in rats and mice) classical, phosphotyrosine-specific 
phosphatases (Figure 1). The remaining approximately 65 members are defined as DSPs, 
based on their ability in vitro to dephosphorylate both tyrosine and serine/threonine 
phosphorylated substrates. The DSPs include the MKPs and PTEN, which dephosphorylates 
the 3' position in phosphatidylinositol (3,4,5)-triphosphate to attenuate PI3K signaling [6, 117]. 
The classical PTPs can exist as non-transmembrane cytosolic PTPs that have regulatory 
sequences flanking their catalytic domains, and transmembrane receptor-like PTPs that have 
transmembrane and extracellular domains with the potential to bind ligand [6, 117]. The 
cytosolic PTPs include the prototypic PTP1B (PTPN1), which is targeted to the cytoplasmic 
face of the endoplasmic reticulum (ER), and TCPTP (PTPN2), which can exist as two variants 
targeted to the ER and nucleus by alternate non-catalytic C termini [6, 117]. 
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GLOSSARY: 
 
AgRP; agouti-related peptide, a neuropeptide produced by AgRP/NPY neurons that promote 
feeding. AgRP inhibits POMC neurons and antagonises α-MSH binding to MC4R. 
AMPK; AMP-activated protein kinase 
ARC; arcuate nucleus, an aggregation of neurons located in the mediobasal hypothalamus 
Cellular leptin resistance; refers to the diminished responsiveness of ARC neurons to 
circulating leptin 
CNS; central nervous system 
CSF; cerebrospinal fluid 
DSPs; dual-specificity phosphatases  
FoxO1; forkhead box O1 
GABA; γ-aminobutyric acid 
ICV; intracerebroventricular, within the ventricle of the brain 
IRS; IR substrate 
IR Y1162/Y1163 site; tyrosine phosphorylation site on the insulin receptor tyrosine kinase 
activation loop required for insulin receptor activation 
JAK2; Janus-activated kinase 2  
LEPR-B; long form of leptin receptor  
MAPK; mitogen activated protein kinase 
MC4R; melanocortin-4 receptor, receptor for α-MSH 
MKPs; MAPK phosphatases 
α-MSH; α-melanocyte-stimulating hormone, a neurotransmitter derived from POMC that 
agonises MC4Rs on second order neurons in the PVN 
NPY; neuropeptide Y, a neurotrasmitter 
PTEN; phosphatase and tensin homologue  
PI3K; phosphatidyinositol 3-kinase  
POMC; proopiomelanocortin, a neuropeptide that is produced by POMC neurons and is the 
precursor of α-MSH 
PTPN1; gene encoding PTP1B 
PTPN2; gene encoding TCPTP 
PVN; paraventricular nucleus, a hypothalamic neuronal nucleus with afferent inputs from first 
order POMC and AgRP/NPY ARC neurons 
SH2; protein domain that bind phosphotyrosine in a specific context 
SOCS3; suppressor of cytokine signaling 3 
STAT3; signal transducer and activator of transcription-3, a transcription factor that is 
phosphorylated by JAK-2 and mediates leptin-induced gene expression  
substrate-trapping mutant; inactive PTP mutant that can bind substrates stably 
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FIGURE LEGENDS 
Figure 1. Schematic of classical PTPs. The classical PTPs catalyse the dephosphorylation of 
tyrosyl phosphorylated protein substrates and include 38 family members (37 in humans) that 
are subdivided into non-transmembrane, cytosolic PTPs (17 members) and transmembrane 
receptor-like PTPs (21 members). The non-transmembrane, cytosolic PTPs have regulatory, 
substrate interaction and targeting sequences flanking their single catalytic domains, whereas 
the transmembrane receptor-like PTPs have one or two catalytic domains (the membrane distal 
PTP domain is often inactive or has residual activity and referred to as a PTP 
pseudophosphatase domain), in some cases juxtamembrane domains, single-pass 
transmembrane domains and variable extracellular domains, some of which bind ligand. The 
catalytic domains of all classical PTPs are characterised by the [I/V]HCXXGXXR[S/T] 
signature motif, in which the Cys and Arg residues are essential for catalytic activity. 
Abbreviations: BRO-1, BRO-1 homology; CAH, carbonic anhydrase-like; Cad, cadherin-like 
juxtamembrane sequence; FERM, FERM (4.1/ezrin/radixin/moesin) domain; FN, fibronectin 
type III-like domain; Gly, glycosylated; HD, histidine domain; Ig, immunoglobulin domain; 
KIM, kinase-interacting motif; MAM, mephrin/A5/μ domain; Pro, proline-rich; RGDS, RGDS-
adhesion recognition motif; SEC14, SEC14/cellular retinaldehyde-binding protein-like; SH2, 
Src homology 2.  
 
Figure 2. CNS insulin and leptin signaling in energy expenditure and glucose homeostasis. 
The circulating adipokine leptin and the hormone insulin communicate to the ARC and 
hypothalamus the organisms peripheral energy reserves and metabolic status.  Leptin and 
insulin are transported to the hypothalamus/ARC across a blood brain barrier and specialised 
glial cells known as tanycytes. Within the ARC leptin and insulin engage their respective 
receptors (LEPR-B, IR) on two opposing neuronal populations known as POMC and 
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AgRP/NPY neurons. POMC neuronal activation represses food intake and promotes 
expenditure whereas AgRP stimulates food intake. The neuropeptide POMC is processed to α-
MSH and acts on the MCR4 receptor on second order hypothalamic neurons in the PVN.  
AgRP/NPY inhibit POMC neuronal activation and antagonise the α-MSH/MCR4 interaction. 
These signals are propagated to the rest of the brain and peripheral tissue such as WAT, BAT, 
pancreas, muscle and the liver to regulate food intake, whole-body energy expenditure and 
metabolism. Abbreviations: α-MSH, alpha-melanocyte-stimulating hormone; AgRP, Agouti-
related peptide; ARC, Arcuate nucleus; MC4R, Melanocortin 4 receptor; POMC, pro-
opiomelanocortin; PVN; Paraventricular nucleus; NPY, neuropeptide Y. 
 
Figure 3. PTPs attenuate CNS insulin and leptin signalling.  Leptin and insulin signal in 
hypothalamic neurons via the JAK2/STAT3 and JAK2/IRS-2/PI3K pathways to promote the 
expression of the anorexigenic (appetite suppressant) neuropeptide POMC and repress the 
expression of the orexigenic neuropeptides AgRP and NPY.  Leptin and insulin also signal via 
the JAK2/IRS-2/PI3K pathway 1) to stimulate ATP sensitive K+ channels (KATP) to alter the 
electrical activity of POMC and AgRP neurons, and 2) to activate the protein kinase AKT to 
regulate glucose metabolism.  These pathways are attenuated by the classical PTPs PTP1B, 
PTPe and TCPTP, the DSP PTEN, which dephosphorylates the lipid products of PI3K, and by 
SOCS3.  PTP1B and TCPTP act together to attenuate leptin-induced JAK2/STAT3 signalling 
with PTP1B dephosphorylating the Y1007/Y1008 PTK activation loop site on JAK2 which is 
associated with the leptin receptor, and TCPTP the Y705 phosphorylation site on STAT3 that 
is required for STAT3 dimerisation and translocation to the nucleus where it mediates effects 
on gene expression. PTP1B and TCPTP also dephosphorylate the Y1162/Y1163 PTK 
activation loop site on the insulin receptor to attenuate insulin signaling.  
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Figure 4. CNS control of WAT browning and energy expenditure. In periods of positive 
energy balance when leptin and insulin levels are elevated, leptin and insulin act synergistically 
on POMC neurons to promote the conversion of white fat into beige fat, referred to as WAT 
browning, and the expenditure of energy to maintain body weight. In obesity when 
hypothalamic PTP1B and TCPTP levels are elevated, leptin and insulin signalling are 
attenuated resulting in diminished WAT browning, decreased energy expenditure and increased 
weight gain.  
 
Figure 5. PTP1B and TCPTP inhibitors. The figure depicts the structures of PTP1B inhibitors, 
compounds 1 [100], 2 [101], 4 [104], 5 [105], and 6 (also known as trodusquemine and MSI-
1436) [93], the TCPTP inhibitor compound 7 [111] and a PTP1B and TCPTP dual inhibitor 
compound 3 [103].  
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